You are here

CDC Updates Guidelines on Sexually Transmitted Disease

Agency notes that treatment is complicated by antimicrobial resistance

The agency’s revised guidelines were published in the August 10 issue of Morbidity and Mortality Weekly Report.

For the treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea, the CDC now recommends combination therapy with a single intramuscular dose of ceftriaxone 250 mg plus either a single dose of azithromycin 1 g orally or doxycycline 100 mg orally twice daily for 7 days.

When ceftriaxone cannot be used for the treatment of urogenital or rectal gonorrhea, two alternative options are available: 1) cefixime 400 mg orally plus either azithromycin 1 g orally or doxycycline 100 mg twice daily orally for 7 days if ceftriaxone is not readily available, or 2) azithromycin 2 g orally in a single dose if ceftriaxone cannot be given because of severe allergy.

Gonorrhea is a major cause of serious reproductive complications in women and can facilitate the transmission of human immunodeficiency virus (HIV). Effective treatment is a cornerstone of U.S. gonorrhea control efforts, the CDC says, but treatment of the disease has been complicated by the ability of Neisseria gonorrhoeae to develop antimicrobial resistance.

For more information, visit the CDC Web site.

Recent Headlines

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial